Postpone Meeting: I have another clash, and we can deal with many things here.
Specifically:
Further to Lee Graves's presentation last time, he sent through summary data, which I've uploaded. He says "Karim summarized the major changes for 28 (the active) and compared these relative to 26 (the inactive) and dinaciclib. Please take a look and let me know what you think. He also checked for any “complete” competition results where there were no peptides. Only CDK9 showed this at the highest concentration- which would be expected." My follow-up questions to Lee were:
"1) Could we have the original data behind the powerpoint? Kind of a point of principle for us... (now done).
2) The first sheet looks like this is a summary of those kinases for which there are the biggest differences between 26 (inactive) and 28 (active), is that right? And where the 28 response is dose-dependent? Or is this a different kind of summary (we saw more panels in the meeting, as I recall).
3) I think you said in the meeting you were going to repeat this screen to check the results, is that right? i.e. we ought to wait for that before concluding too much?
4) Once we have the parallel scan for MRSA, I think we're done in terms of getting the paper out. Is that possible? Grant formally finishes at the end of Dec - shall I request extra time?"
Other things ongoing:
[ ] Samples incoming from @QSimpson and @edwintse will keep to Jan, when Paul Stapleton is happy to screen. @edwintse to organise date for this with Paul in first week in Jan.
[ ] Have we had these compounds evaluated in a kinase panel screen?
[ ] Everyone is encouraged to look at the draft paper posted by @danaklug and contribute/comment #101
[ ] Anyone used/want to use the Discussions function, above?
[ ] @mattodd to post latest meeting(s) to Youtube - slight backlog.
[x] @danaklug will assemble the Christmas Open Source Antibiotics newsletter, which will have 3 science updates from this series as well as three from the mur ligase project. Keep an eye out for this - the newsletter needs to be short and sweet and understandable by someone who is not closely following the project detail.
Postpone Meeting: I have another clash, and we can deal with many things here.
Specifically:
Further to Lee Graves's presentation last time, he sent through summary data, which I've uploaded. He says "Karim summarized the major changes for 28 (the active) and compared these relative to 26 (the inactive) and dinaciclib. Please take a look and let me know what you think. He also checked for any “complete” competition results where there were no peptides. Only CDK9 showed this at the highest concentration- which would be expected." My follow-up questions to Lee were:
"1) Could we have the original data behind the powerpoint? Kind of a point of principle for us... (now done). 2) The first sheet looks like this is a summary of those kinases for which there are the biggest differences between 26 (inactive) and 28 (active), is that right? And where the 28 response is dose-dependent? Or is this a different kind of summary (we saw more panels in the meeting, as I recall). 3) I think you said in the meeting you were going to repeat this screen to check the results, is that right? i.e. we ought to wait for that before concluding too much? 4) Once we have the parallel scan for MRSA, I think we're done in terms of getting the paper out. Is that possible? Grant formally finishes at the end of Dec - shall I request extra time?"
Other things ongoing:
Next meeting: let's make it 2pm UK time Jan 14th.